Literature DB >> 8640565

Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.

J M Wilson1, K S Kalasinsky, A I Levey, C Bergeron, G Reiber, R M Anthony, G A Schmunk, K Shannak, J W Haycock, S J Kish.   

Abstract

Methamphetamine is a drug that is significantly abused worldwide, Although long-lasting depletion of dopamine and other dopamine nerve terminal markers has been reported in striatum of nonhuman primates receiving very high doses of the psychostimulant, no information is available for humans. We found reduced levels of three dopamine nerve terminal markers (dopamine, tyrosine hydroxylase and the dopamine transporter) in post-mortem striatum (nucleus accumbens, caudate, putamen) of chronic methamphetamine users. However, levels of DOPA decarboxylase and the vesicular monoamine transporter, known to be reduced in Parkinson's disease, were normal. This suggests that chronic exposure to methamphetamine does not cause permanent degeneration of striatal dopamine nerve terminals at the doses used by the young subjects in our study. However, the dopamine reduction might explain some of the dysphoric effects of the drug, whereas the decreased dopamine transporter could provide the basis for dose escalation occurring in some methamphetamine users.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640565     DOI: 10.1038/nm0696-699

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  248 in total

1.  Acceleration of HIV dementia with methamphetamine and cocaine.

Authors:  A Nath; W F Maragos; M J Avison; F A Schmitt; J R Berger
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

2.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

3.  Dopaminergic system dysfunction in recreational dexamphetamine users.

Authors:  Anouk Schrantee; Lena Václavů; Dennis F R Heijtel; Matthan W A Caan; Willy Gsell; Paul J Lucassen; Aart J Nederveen; Jan Booij; Liesbeth Reneman
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 4.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

5.  Altered learning and Arc-regulated consolidation of learning in striatum by methamphetamine-induced neurotoxicity.

Authors:  Elissa D Pastuzyn; David E Chapman; Karen S Wilcox; Kristen A Keefe
Journal:  Neuropsychopharmacology       Date:  2011-11-09       Impact factor: 7.853

6.  Age-dependent effects of neonatal methamphetamine exposure on spatial learning.

Authors:  Charles V Vorhees; Matthew R Skelton; Michael T Williams
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

7.  Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation.

Authors:  Govinder Flora; Yong Woo Lee; Avindra Nath; William Maragos; Bernhard Hennig; Michal Toborek
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

8.  Effect of methamphetamine neurotoxicity on learning-induced Arc mRNA expression in identified striatal efferent neurons.

Authors:  David P Daberkow; Matthew D Riedy; Raymond P Kesner; Kristen A Keefe
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

9.  Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice.

Authors:  J P Q Zhu; W Xu; J A Angulo
Journal:  Neuroscience       Date:  2006-05-02       Impact factor: 3.590

10.  Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene.

Authors:  Eun-Joo Shin; Seung Woo Shin; Thuy-Ty Lan Nguyen; Dae Hun Park; Myung-Bok Wie; Choon-Gon Jang; Seung-Yeol Nah; Byung Wook Yang; Sung Kwon Ko; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Mol Neurobiol       Date:  2014-01-16       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.